Study type: In vitro · Status: Verified against declared source

A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.

Biosensors · 2023

Study scale: Not reported

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Barrier integrity of the epithelium was qualitatively evaluated through ZO-1 and occludin immunostaining.

Methods

After six days of experimental conditions, cellular lysates were prepared using RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) containing phosphatase and protease inhibitors (Thermo Fisher Scientific, Waltham, MA, USA), then centrifuged at 14,000× g for 15 min.

Scale or participants

Not reported in the reviewed source.

Key findings

Despite the prevalence of diabetic retinopathy, the majority of adult diabetic patients develop visually debilitating corneal complications, including impaired wound healing.

Limitations and uncertainty

Despite the prevalence of diabetic retinopathy, the majority of adult diabetic patients develop visually debilitating corneal complications, including impaired wound healing.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.